April 27, 2020 / 4:21 PM / a month ago

BRIEF-Noxxon Presents Clinical Data From Phase 1/2 Nox-A12 / Keytruda® Trial

April 27 (Reuters) - NOXXON PHARMA NV:

* NOXXON PRESENTS LATEST CLINICAL DATA FROM THE PHASE 1/2 NOX-A12 / KEYTRUDA® COMBINATION TRIAL IN COLORECTAL AND PANCREATIC CANCER AT THE AACR VIRTUAL ANNUAL MEETING 2020

* DATA INDICATE THAT TREATMENT WITH NOX-A12 PLUS PEMBROLIZUMAB IN COMBINATION THERAPY PART OF STUDY RESULTED IN STABLE DISEASE IN 25% OF PATIENTS AND PROLONGED TIME ON TREATMENT VERSUS. PRIOR THERAPY FOR 35% OF PATIENTS

* SAFETY PROFILE OF COMBINATION THERAPY WAS CONSISTENT WITH THAT OF PEMBROLIZUMAB IN ADVANCED CANCER PATIENTS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below